Home

Pipeline

Technology

The team

News

Contact

The Team

Tiffany Thorn BSc. MSc. – Chief Executive Officer

Tiffany Thorn, inventor of the company’s ‘Bi-Cygni Dual Targeting Technology’, leads BiVictriX’s operations as CEO.

As Founder of BiVictriX Therapeutics, Tiffany has successfully lead the Company through the first 18 months of operations, meeting key technical milestones opposite the Lead Candidate and securing two rounds of funding. Tiffany was previously Marketing and Licensing Manager at ADC Biotechnology Ltd., gaining vital experience of the ADC market and key trends in the sector, before establishing BiVictriX in December 2016.

As a HCPC registered Clinical Immunologist, Tiffany has experience of diagnosing and treating haematological malignancy within a clinical setting and spent several years carrying out this role in the NHS. During this time, Tiffany was awarded the Chief Scientific Officer’s ‘Rising Star Award’ in 2014 for recognition of her work in establishing a regional network to support NHS: Industry collaboration, which was spun out nationally. Tiffany also previously held several technical positions at RedX Pharma Plc, a drug development company focused on the Redox Switch™ technology platform.

Tiffany graduated from Lancaster University with a first class BSc Hons. In Biochemistry with Biomedicine and later gained a MSc Distinction in Clinical Immunology at the University of Manchester.

David Youngman – Non-Executive Director

David has almost 35 years’ experience in stockbroking and corporate finance and will bring corporate finance advise and strong governance practices to BiVictriX in his role as non-executive Director.

David currently holds the position of Corporate Finance Director at Acceleris Capital Ltd., part of Seneca Partners, an Investment Management and Corporate Advisory services group which specialises in the SME sector.

From May 1995 to 2009, David was Managing Director and Head of Corporate Finance at WH Ireland. During that period, WH Ireland grew from one office with a turnover of less than £1 million to 12 UK offices and an Australian subsidiary with turnover in excess of £30 million.

David, over the course of the last nine years of his stockbroking career, was responsible for a portfolio of over 60 companies admitted to AIM.

Chris Doherty, B.Pharm. PhD. MBA – Non-Executive Chairman

Chris Doherty, a life science leader with over 26 years’ experience in the pharmaceutical industry, brings drug development expertise and strong corporate governance to the board.

Chris has previously held several senior roles in three large pharma organisations, including both of the UKs largest companies; Glaxo in Canada/UK working in Development and Production roles before moving to Roche as Head of Pharmacy R&D for the UK. Chris joined AstraZeneca in 1997 to lead an international pharmaceutical sciences R&D group. This was followed by broader experience running R&D/commercial/clinical teams for late phase development projects in oncology, managing the global late phase decision making body, as well as a site leadership role at Alderley Park. During this time, Chris has worked on over 8 projects which have gone to market.

Chris is currently Managing Director at Alderley Park, now owned by Bruntwood, and is responsible for the science park, C-Level company engagement and investment fund aspects.

Chris graduated as a Pharmacist and completed his PhD at School of Pharmacy, Bradford University, completed a Post-Doctoral Fellowship in pharmaceutical technology at the University of Toronto, Canada and subsequently gained an MBA.

Cath Eberlein BSc. MSc. - Senior Scientist

Cath Eberlein, a peer reviewed molecular and cellular biologist with over 25 years’ Drug Discovery experience, is responsible for driving the in vitro biology strategy of the Company.

Cath previously spent over 21 years working in in vitro biology areas across small and large molecule Cardiovascular and Oncology projects within AstraZeneca and with MedImmune. With Cath’s involvement in projects across the drug discovery process she became accomplished in a wide range of skills and developed a flexible approach to new technologies and novel assay development. During this time Cath was awarded the AstraZeneca Scientist of the Year (2013) for her novel investigations into resistance to EGFR inhibitors.

More recently Cath has spent over 2 years working within the Drug Discovery Unit at the CRUK Manchester Institute, identifying and validating novel epigenetic drug targets in Lung Cancer.

Cath graduated from Surrey University with a first class BSc. Hons Degree in Biochemistry  and later gained a MSc. in Oncology undertaken at the Paterson Institute for Cancer Research and awarded by Manchester University.

George Orphanides BSc. PhD. – Chief Scientific Officer

George Orphanides, a life science leader and oncology specialist with 18 years’ experience in the pharmaceutical industry, is responsible for driving the scientific strategy of the Company.

George has held a number of senior leadership positions at AstraZeneca, including Director of Oncology Translational Science, Head of Alliances and Partnerships and Global Disease Area Leader for a number of priority indications, including Lung and Colorectal cancers. George also has experience with novel therapeutic technologies, having led a team responsible for reviewing and prioritising new drug platforms, such as Antibody-Drug Conjugates, Nucleic Acids, Peptides and Vaccines.

During his time in the pharmaceutical industry, George worked across a large and diverse portfolio of oncology projects, from target identification through to clinical development and product launch. He also established a number of key alliances with cancer centres in Europe, Asia and the US and has served on prominent consortia and review bodies, including Cancer Core Europe, EIT Health and the MATWIN organization.

George has a PhD from the University of Leicester and conducted his post-doctoral training as a Fellow of the Howard Hughes Medical Institute in the US, focusing on the epigenetic regulation of transcription in cancer cells.

BiVictriX Therapeutics Ltd. Bio Hub, Alderley Park, Alderley Edge, Cheshire SK10 4TG, UK

+44 (0) 7908 719 566   info@bivictrix.com